c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
Tvardi Therapeutics (TVRD) Advances Oral STAT3 Inhibitor TTI-109 Toward Phase 2 Trials for IBD
GuruFocus | Nov 19, 2026 8:28 AM EST
Related Stocks: TVRD ,
Read original article